LRRK2 kinase inhibitors (Cerevel therapeutics)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameLRRK2 kinase inhibitors (Cerevel therapeutics)
Drug Alias NameLRRK2 kinase inhibitors (Pfizer)PF-360PFE-475PFE-360
ClassificationSmall molecules
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitorsNeuroprotectants
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCerevel Therapeutics IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A